読み込み中
HCW Biologics Inc. operates as a preclinical-stage biopharmaceutical firm, primarily engaged in the discovery and advancement of novel immunotherapies. Its research and development efforts are focused on addressing chronic, low-grade inflammation and a spectrum of age-related diseases. The company's leading therapeutic candidates include HCW9218, an injectable immunotherapeutic designed for patients with a variety of cancers, such as pancreatic, ovarian, breast, prostate, and colorectal, as well as for pulmonary fibrosis. Another key product, HCW9302, targets autoimmune conditions like alopecia areata and various metabolic disorders. Beyond these, HCW Biologics is also developing HCW9201, a cell-based therapy currently in Phase II clinical trials for the treatment of relapsed/refractory acute myeloid leukemia. Additionally, HCW9206 is under development specifically for acute myeloid leukemia. Incorporated in 2018, the company's corporate headquarters are situated in Miramar, Florida.
前日終値
$1.60
+$0.07 · +4.58%
日中の時刻はETです。市場データは遅延する場合があります。
HCW Biologics Inc. operates as a preclinical-stage biopharmaceutical firm, primarily engaged in the discovery and advancement of novel immunotherapies. Its research and development efforts are focused on addressing chronic, low-grade inflammation and a spectrum of age-related diseases. The company's leading therapeutic candidates include HCW9218, an injectable immunotherapeutic designed for patients with a variety of cancers, such as pancreatic, ovarian, breast, prostate, and colorectal, as well as for pulmonary fibrosis. Another key product, HCW9302, targets autoimmune conditions like alopecia areata and various metabolic disorders. Beyond these, HCW Biologics is also developing HCW9201, a cell-based therapy currently in Phase II clinical trials for the treatment of relapsed/refractory acute myeloid leukemia. Additionally, HCW9206 is under development specifically for acute myeloid leukemia. Incorporated in 2018, the company's corporate headquarters are situated in Miramar, Florida.
日中レンジ
現在 $1.60
52週レンジ
現在 $1.60
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
46
適正価値
センチメント
61
強気
リスク
80
高リスク
モメンタム
17
強い下落
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
HCW Biologics Inc. operates as a preclinical-stage biopharmaceutical firm, primarily engaged in the discovery and advancement of novel immunotherapies. Its research and development efforts are focused on addressing chronic, low-grade inflammation and a spectrum of age-related diseases. The company's leading therapeutic candidates include HCW9218, an injectable immunotherapeutic designed for patients with a variety of cancers, such as pancreatic, ovarian, breast, prostate, and colorectal, as well as for pulmonary fibrosis. Another key product, HCW9302, targets autoimmune conditions like alopecia areata and various metabolic disorders. Beyond these, HCW Biologics is also developing HCW9201, a cell-based therapy currently in Phase II clinical trials for the treatment of relapsed/refractory acute myeloid leukemia. Additionally, HCW9206 is under development specifically for acute myeloid leukemia. Incorporated in 2018, the company's corporate headquarters are situated in Miramar, Florida.
日中レンジ
現在 $1.60
52週レンジ
現在 $1.60
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 5.42万 USD | 256.68万 USD | 284.18万 USD | 672.21万 USD | — |
| 売上原価 | 4.34万 USD | 160.74万 USD | 228.14万 USD | 413.57万 USD | — |
| 粗利益 | 1.08万 USD | 95.94万 USD | 56.04万 USD | 258.64万 USD | — |
| 研究開発 | 544.29万 USD | 638.9万 USD | 767.63万 USD | 933.84万 USD | 817.36万 USD |
| 販売・一般管理 | 770.13万 USD | 2194.52万 USD | 1308.44万 USD | 798.83万 USD | 530.22万 USD |
| 営業費用 | 1126.81万 USD | 3043.91万 USD | 2627.75万 USD | 1766.52万 USD | 1336.78万 USD |
| 受取利息 | — | — | — | — | 50.54万 USD |
| 支払利息 | 125.03万 USD | 115.84万 USD | 28.3万 USD | 12.67万 USD | — |
| 減価償却費と償却費 | 104.18万 USD | 118.44万 USD | 113.52万 USD | 71.79万 USD | 54.36万 USD |
| 営業利益 | −1125.73万 USD | −2947.97万 USD | −2571.72万 USD | −1507.88万 USD | −1336.78万 USD |
| 純利益 | −795.97万 USD | −3002.38万 USD | −2499.43万 USD | −1490.07万 USD | −1286.25万 USD |
会社概要が更新されました 2026年10月12日.
発表済み実績と利用可能なコンセンサス予想。
発表済み実績と利用可能なコンセンサス予想。
この株式へのエクスポージャーを報告している上場投資信託です。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
